The Telegraph – One of America’s leading biotechs, Bluebird Bio, is in talks with UK medicine regulators about a potential launch of its pioneering range of gene therapies for rare diseases.
Bluebird has a market value of over $4bn (£3bn) on New York’s Nasdaq stock exchange and specialises in bone marrow transplants to cure patients with faulty immune systems.
Diseases it is trying to cure include severe sickle cell disease and neurological disorder adrenoleukodystrophy, as well as treatments for multiple myeloma, a plasma cell cancer.
Its technology is still undergoing clinical trials, but Bluebird told The Daily Telegraph the company is eyeing a launch in Europe before its home market.
Read more at The Telegraph.